Recent Updates
Recently added Catalysts
PMN

ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease

Tuesday, September 19, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: TORONTO and CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- ERN UK

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+98%
120-day peak, hindsight
Typical move
16.6%
average across 4 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
PMN310
Phase 1 · Healthy Participants

Full Press Release Details

TORONTO and CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- ERN UK
ShareAdd on Google
Tags: PMN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 19, 2017

Biotech snapshot

Cash runway
$53M liquidity · $3M/mo burn
~15 mo
Low dilution risk
Lead asset
PMN310Phase 1
Healthy Participants →

Catalyst track record

+98%
best trade around PMN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PMN.

See every catalyst's timing & PoA →